logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Kho S, Seung KJ, Huerga H, Bastard M, Khan PY,  et al.
2024-05-09 • Nature Communications
2024-05-09 • Nature Communications
Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT032592...
Journal Article
|
Research

Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis

Trevisi L, Hernán MA, Mitnick CD, Khan UT, Seung KJ,  et al.
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...
Conference Material
|
Video

MDR-TB care outcomes in Mumbai and Myanmar – Joint interview

Kalon S, Iyer AS, Zarli K
2021-08-25 • MSF Scientific Days Asia 2021
2021-08-25 • MSF Scientific Days Asia 2021
Journal Article
|
Research

Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study

Franke MF, Khan P, Hewison C, Khan U, Huerga H,  et al.
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...
Journal Article
|
Research

Culture conversion in patients treated with bedaquiline and/or delamanid: A prospective multi-country study

Franke MF, Khan PY, Hewison CCH, Khan UT, Huerga H,  et al.
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
BACKGROUND
Bedaquiline and delamanid offer the possibility of more effective and less toxic multidrug-resistant tuberculosis (MDR-TB) treatment. With this treatment, however, some pa...
Journal Article
|
Research

Setting up pharmacovigilance based on available endTB project data for bedaquiline

Lachenal N, Hewison CCH, Mitnick CD, Lomtadze N, Coutisson S,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched with the support of UNIT...